《美國股市》禮來美股市值直逼強生 1997年後從未超過
據道瓊斯市場數據,禮來(LLY.US)周五(12日)的市值直逼強生(JNJ.US),禮來市值自1997年10月以來從未超過強生。
禮來自今年5月初公布阿茲海默氏症新藥,表明可以減輕早期阿茲海默氏症症狀患者的症狀,包括認知和功能降幅顯著減緩後,股價一直穩步上揚,今年迄今禮來股價股價上漲約20%,過去12個月上漲50%,現時市值4134.6億美元。
強生則仍受爽身粉事件影響,第一季度出現虧損,今年迄今股價下跌9%,過去12個月跌幅相若,現時市值4183.7億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.